{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:09:24Z","timestamp":1790813364666,"version":"4.1.0"},"reference-count":294,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.phrs.2024.107408","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T01:42:36Z","timestamp":1726882956000},"page":"107408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Multitarget ligands that comprise opioid\/nonopioid pharmacophores for pain management: Current state of the science"],"prefix":"10.1016","volume":"209","author":[{"given":"\u00c9mile","family":"Breault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Desgagn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien De","family":"Neve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.A.","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ballet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Sarret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2024.107408_bib1","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.phrs.2024.107408_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108019","article-title":"Treatment of overdose in the synthetic opioid era","volume":"233","author":"Skolnick","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib3","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/jacs.8b09756","article-title":"Chemical interventions for the opioid crisis: key advances and remaining challenges","volume":"141","author":"Olson","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2024.107408_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2024.107408_bib5","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/add.12598","article-title":"The burden of premature opioid-related mortality","volume":"109","author":"Gomes","year":"2014","journal-title":"Addict. Abingdon Engl."},{"key":"10.1016\/j.phrs.2024.107408_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7812\/TPP\/16-169","article-title":"Physician Guide to Appropriate Opioid Prescribing for Noncancer Pain","volume":"21","author":"Munzing","year":"2017","journal-title":"Perm. J."},{"key":"10.1016\/j.phrs.2024.107408_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/SPC.0000000000000495","article-title":"Opioid analgesia: recent developments","volume":"14","author":"Stein","year":"2020","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.phrs.2024.107408_bib8","first-page":"1473","article-title":"Pharmacological options for the management of refractory cancer pain-what is the evidence?","volume":"23","author":"Afsharimani","year":"2015","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"10.1016\/j.phrs.2024.107408_bib9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2024.107408_bib10","first-page":"17","article-title":"A \u201cnovel\u201d association to treat pain: tramadol\/dexketoprofen. The first drug of a \u201cnew pharmacological class","volume":"88","author":"Fornasari","year":"2017","journal-title":"Acta Bio-Med. Atenei Parm."},{"key":"10.1016\/j.phrs.2024.107408_bib11","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"CIHR Canadian Research Initiative in Substance Misuse, Management of opioid use disorders: a national clinical practice guideline","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ Can. Med. Assoc. J. J. Assoc. Med. Can."},{"key":"10.1016\/j.phrs.2024.107408_bib12","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"R. Vallejo, Opioid complications and side effects","author":"Benyamin","year":"2008","journal-title":"Pain. Physician 11"},{"key":"10.1016\/j.phrs.2024.107408_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jpain.2005.08.001","article-title":"Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study","volume":"7","author":"Chu","year":"2006","journal-title":"J. Pain."},{"key":"10.1016\/j.phrs.2024.107408_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1155\/2002\/323085","article-title":"Chronic pain in Canada--prevalence, treatment, impact and the role of opioid analgesia","volume":"7","author":"Moulin","year":"2002","journal-title":"Pain. Res. Manag."},{"key":"10.1016\/j.phrs.2024.107408_bib15","doi-asserted-by":"crossref","first-page":"j4355","DOI":"10.1136\/bmj.j4355","article-title":"Epidemic of deaths from fentanyl overdose","author":"Soc\u00edas","year":"2017","journal-title":"BMJ 358"},{"key":"10.1016\/j.phrs.2024.107408_bib16","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016","volume":"319","author":"Jones","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2024.107408_bib17","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/add.14474","article-title":"Illicit fentanyls in the opioid street market: desired or imposed?","volume":"114","author":"Mars","year":"2019","journal-title":"Addict. Abingdon Engl."},{"key":"10.1016\/j.phrs.2024.107408_bib18","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(19)30428-3","article-title":"Inappropriate opioid prescription after surgery","volume":"393","author":"Neuman","year":"2019","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.phrs.2024.107408_bib19","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(22)00582-7","article-title":"Opioid versus opioid-free analgesia after surgical discharge: a systematic review and meta-analysis of randomised trials","volume":"399","author":"Fiore","year":"2022","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.phrs.2024.107408_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrn.2016.162","article-title":"Structural plasticity and reorganisation in chronic pain","volume":"18","author":"Kuner","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2024.107408_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107408_bib22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1124\/mi.9.5.7","article-title":"In search of analgesia: emerging roles of GPCRs in pain","volume":"9","author":"Stone","year":"2009","journal-title":"Mol. Interv."},{"key":"10.1016\/j.phrs.2024.107408_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1152\/physrev.00040.2019","article-title":"Cellular circuits in the brain and their modulation in acute and chronic pain","volume":"101","author":"Kuner","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1152\/physrev.00045.2019","article-title":"Neuropathic pain: from mechanisms to treatment","volume":"101","author":"Finnerup","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/ACO.0000000000001370","article-title":"Perioperative pain optimization in the age of the opioid epidemic","volume":"37","author":"Patel","year":"2024","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"10.1016\/j.phrs.2024.107408_bib26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4097\/kja.d.18.00217","article-title":"Designing the ideal perioperative pain management plan starts with multimodal analgesia","volume":"71","author":"Schwenk","year":"2018","journal-title":"Korean J. Anesthesiol."},{"key":"10.1016\/j.phrs.2024.107408_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neubiorev.2021.01.023","article-title":"Glial and neuroimmune cell choreography in sexually dimorphic pain signaling","volume":"125","author":"Midavaine","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105749","article-title":"Sex differences in mechanisms of pain hypersensitivity","author":"Mogil","year":"2024","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jhrm.21262","article-title":"Multimodal analgesia as an alternative to the risks of opioid monotherapy in surgical pain management","volume":"37","author":"Savarese","year":"2017","journal-title":"J. Healthc. Risk Manag. J. Am. Soc. Healthc. Risk Manag."},{"key":"10.1016\/j.phrs.2024.107408_bib30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jpain.2009.12.010","article-title":"The determination and application of fixed-dose analgesic combinations for treating multimodal pain","volume":"11","author":"Raffa","year":"2010","journal-title":"J. Pain."},{"key":"10.1016\/j.phrs.2024.107408_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/00325481.2021.1985351","article-title":"Neuropharmacological basis for multimodal analgesia in chronic pain","volume":"134","author":"Patel","year":"2022","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.phrs.2024.107408_bib32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.anclin.2022.04.002","article-title":"Multimodal Analgesia","volume":"40","author":"O\u2019Neill","year":"2022","journal-title":"Anesthesiol. Clin."},{"key":"10.1016\/j.phrs.2024.107408_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.suc.2021.09.003","article-title":"Multimodal Analgesia in the Era of the Opioid Epidemic","volume":"102","author":"Nicholas","year":"2022","journal-title":"Surg. Clin. North Am."},{"key":"10.1016\/j.phrs.2024.107408_bib34","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/ajhp\/zxaa301","article-title":"Review of nonopioid multimodal analgesia for surgical and trauma patients","volume":"77","author":"George","year":"2020","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"10.1016\/j.phrs.2024.107408_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.anclin.2011.12.002","article-title":"Recent advances in multimodal analgesia","volume":"30","author":"Young","year":"2012","journal-title":"Anesthesiol. Clin."},{"key":"10.1016\/j.phrs.2024.107408_bib36","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/pmt-2021-0116","article-title":"Paracetamol for multimodal analgesia","volume":"12","author":"Freo","year":"2022","journal-title":"Pain. Manag"},{"issue":"9","key":"10.1016\/j.phrs.2024.107408_bib37","first-page":"76","volume":"2000","author":"White","year":"2008","journal-title":"Multimodal Analg.: its role Prev. Postoper. Pain., Curr. Opin. Investig. Drugs Lond. Engl."},{"key":"10.1016\/j.phrs.2024.107408_bib38","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2146\/ajhp130688","article-title":"Perioperative nonopioid agents for pain control in spinal surgery","volume":"71","author":"Rivkin","year":"2014","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"10.1016\/j.phrs.2024.107408_bib39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2147\/JPR.S112626","article-title":"Use of preoperative gabapentin significantly reduces postoperative opioid consumption: a meta-analysis","volume":"9","author":"Arumugam","year":"2016","journal-title":"J. Pain. Res."},{"key":"10.1016\/j.phrs.2024.107408_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.633168","article-title":"Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain","volume":"12","author":"MacCallum","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib41","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41386-022-01322-4","article-title":"Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies","volume":"47","author":"Nielsen","year":"2022","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib42","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1517\/14656566.2012.668531","article-title":"Fixed-dose combinations for emerging treatment of pain","volume":"13","author":"Raffa","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2024.107408_bib43","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.33320","article-title":"Fixed Dose Versus Loose Dose: Analgesic Combinations","author":"Pergolizzi","year":"2023","journal-title":"Cureus 15"},{"key":"10.1016\/j.phrs.2024.107408_bib44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0149-2918(02)85007-X","article-title":"Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain","volume":"24","author":"Palangio","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib45","first-page":"763","article-title":"Tramadol hydrochloride\/acetaminophen combination for the relief of acute pain","volume":"47","author":"Sawaddiruk","year":"2011","journal-title":"Drugs Today Barc. Spain 1998"},{"key":"10.1016\/j.phrs.2024.107408_bib46","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/JPR.S33112","article-title":"Tramadol\/paracetamol fixed-dose combination in the treatment of moderate to severe pain","volume":"5","author":"Pergolizzi","year":"2012","journal-title":"J. Pain. Res."},{"key":"10.1016\/j.phrs.2024.107408_bib47","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0149-2918(00)80047-8","article-title":"Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of postoperative obstetric or gynecologic pain","volume":"22","author":"Palangio","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib48","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2188","article-title":"The trouble with making combination drugs","volume":"5","author":"Frantz","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107408_bib49","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.2147\/JPR.S208082","article-title":"Co-crystals as a new approach to multimodal analgesia and the treatment of pain","volume":"12","author":"Almansa","year":"2019","journal-title":"J. Pain. Res."},{"key":"10.1016\/j.phrs.2024.107408_bib50","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ajps.2020.06.004","article-title":"Drug-drug cocrystals: Opportunities and challenges","volume":"16","author":"Wang","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib51","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.drudis.2016.02.001","article-title":"Multidrug co-crystals: towards the development of effective therapeutic hybrids","volume":"21","author":"Thipparaboina","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2024.107408_bib52","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3390\/biom13121802","article-title":"Combination Drug Therapy for the Management of Chronic Neuropathic Pain","volume":"13","author":"Boccella","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2024.107408_bib53","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/03007995.2023.2276118","article-title":"Co-crystal of tramadol-celecoxib (CTC) for acute moderate-to-severe pain","volume":"40","author":"Langford","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.phrs.2024.107408_bib54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/13543784.2019.1612557","article-title":"Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic","volume":"28","author":"Gascon","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2024.107408_bib55","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.3390\/molecules25235520","article-title":"Multifunctional Opioid-Derived Hybrids in Neuropathic Pain: Preclinical Evidence, Ideas and Challenges","volume":"25","author":"Starnowska-Sok\u00f3\u0142","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2024.107408_bib56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/164_2018_104","article-title":"Multifunctional Opioid Ligands","volume":"247","author":"Anand","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib57","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.2174\/138161281942140105165646","article-title":"Hybrid opioid\/non-opioid ligands in pain research","volume":"19","author":"Kleczkowska","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2024.107408_bib58","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2174\/1389557517666161111110121","article-title":"Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders","volume":"17","author":"Matias","year":"2017","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/128_2010_76","article-title":"Twin and triplet drugs in opioid research","volume":"299","author":"Fujii","year":"2011","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib60","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1001\/archinte.1990.00390200073014","article-title":"The Effect of Prescribed Daily Dose Frequency on Patient Medication Compliance","volume":"150","author":"Eisen","year":"1990","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.phrs.2024.107408_bib61","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/bja\/aep129","article-title":"Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile","volume":"103","author":"Dietis","year":"2009","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.phrs.2024.107408_bib63","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.4155\/fmc.15.156","article-title":"The design of multitarget ligands for chronic and neuropathic pain","volume":"7","author":"Dvoracsko","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib64","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2015.11.028","article-title":"Multitarget opioid ligands in pain relief: New players in an old game","volume":"108","author":"Turnaturi","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib65","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41594-022-00797-5","article-title":"Structural insight into apelin receptor-G protein stoichiometry","volume":"29","author":"Yue","year":"2022","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.phrs.2024.107408_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/med.22050","article-title":"Bivalent and bitopic ligands of the opioid receptors: The prospects of a dual approach","author":"Hovah","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-018-0259-z","article-title":"Structural insights into G-protein-coupled receptor allostery","volume":"559","author":"Thal","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107408_bib68","article-title":"Inhibition of endothelin A receptor by a novel, selective receptor antagonist enhances morphine-induced analgesia: Possible functional interaction of dimerized endothelin A and \u03bc-opioid receptors, Biomed. Pharmacother","volume":"141","author":"Kuroda","year":"2021","journal-title":"Biomedecine Pharm."},{"key":"10.1016\/j.phrs.2024.107408_bib69","doi-asserted-by":"crossref","first-page":"7702","DOI":"10.1021\/acs.jmedchem.1c00408","article-title":"Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity","volume":"64","author":"Huang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib70","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1021\/acsmedchemlett.0c00444","article-title":"Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry","volume":"11","author":"Ma","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107408_bib71","doi-asserted-by":"crossref","first-page":"20115","DOI":"10.1073\/pnas.1009923107","article-title":"Formation of mu-\/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia","volume":"107","author":"Chakrabarti","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2024.107408_bib72","first-page":"2401","article-title":"Angiotensin II inhibits DDAH1-nNOS signaling via AT1R and \u03bcOR dimerization to modulate blood pressure control in the central nervous system","volume":"133","author":"Sun","year":"2019","journal-title":"Clin. Sci. Lond. Engl. 1979"},{"key":"10.1016\/j.phrs.2024.107408_bib73","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/biom9080368","article-title":"Heterodimerization of Mu Opioid Receptor Protomer with Dopamine D2 Receptor Modulates Agonist-Induced Internalization of Mu Opioid Receptor","volume":"9","author":"Vasudevan","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2024.107408_bib74","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00213-013-3389-x","article-title":"5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function","volume":"231","author":"Garcia-Garcia","year":"2014","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.phrs.2024.107408_bib75","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1021\/jm800174p","article-title":"Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands","volume":"52","author":"Zheng","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib76","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjp.0706757","article-title":"mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis","volume":"148","author":"Rios","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib77","doi-asserted-by":"crossref","first-page":"19762","DOI":"10.1074\/jbc.M110373200","article-title":"Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization","volume":"277","author":"Pfeiffer","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib78","doi-asserted-by":"crossref","first-page":"51630","DOI":"10.1074\/jbc.M307095200","article-title":"Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization","volume":"278","author":"Pfeiffer","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/srep18198","article-title":"Structural and functional interactions between six-transmembrane \u03bc-opioid receptors and \u03b22-adrenoreceptors modulate opioid signaling","volume":"5","author":"Samoshkin","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2024.107408_bib80","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/ijms24021048","article-title":"Opioid-Modulated Receptor Localization and Erk1\/2 Phosphorylation in Cells Coexpressing \u03bc-Opioid and Nociceptin Receptors","volume":"24","author":"Zhuo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib81","doi-asserted-by":"crossref","first-page":"29969","DOI":"10.1039\/C8CP06652C","article-title":"Probing the cooperative mechanism of the \u03bc-\u03b4 opioid receptor heterodimer by multiscale simulation","volume":"20","author":"Wang","year":"2018","journal-title":"Phys. Chem. Chem. Phys. PCCP"},{"key":"10.1016\/j.phrs.2024.107408_bib82","doi-asserted-by":"crossref","first-page":"11595","DOI":"10.1073\/pnas.1305461110","article-title":"Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception","volume":"110","author":"Akg\u00fcn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2024.107408_bib83","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bph.12663","article-title":"Heteromers of \u03bc-\u03b4 opioid receptors: new pharmacology and novel therapeutic possibilities","volume":"172","author":"Fujita","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib84","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev-pharmtox-011613-135952","article-title":"G Protein-Coupled Receptor Heteromers","volume":"56","author":"Gomes","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.phrs.2024.107408_bib85","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/pr.113.008052","article-title":"G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives","volume":"66","author":"Ferr\u00e9","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib86","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2174\/092986608785133672","article-title":"Multiple ligands in opioid research","volume":"15","author":"Ballet","year":"2008","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.phrs.2024.107408_bib87","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/pr.114.008979","article-title":"Molecular Pharmacology of \u03b4-Opioid Receptors","volume":"68","author":"Gendron","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib88","doi-asserted-by":"crossref","first-page":"19208","DOI":"10.1073\/pnas.0506627102","article-title":"Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series","volume":"102","author":"Daniels","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2024.107408_bib89","doi-asserted-by":"crossref","first-page":"12072","DOI":"10.1073\/pnas.1222044110","article-title":"Identification of a \u03bc-\u03b4 opioid receptor heteromer-biased agonist with antinociceptive activity","volume":"110","author":"Gomes","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2024.107408_bib90","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1172\/JCI70647","article-title":"Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties","volume":"124","author":"Demeule","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2024.107408_bib91","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7150\/thno.17155","article-title":"Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor","volume":"7","author":"Hultqvist","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2024.107408_bib92","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1021\/acs.molpharmaceut.2c00523","article-title":"Peptides as Pharmacological Carriers to the Brain: Promises, Shortcomings and Challenges","volume":"19","author":"Parrasia","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.phrs.2024.107408_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105641","article-title":"Novel bivalent ligands carrying potential antinociceptive effects by targeting putative mu opioid receptor and chemokine receptor CXCR4 heterodimers","volume":"120","author":"Ma","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib94","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1021\/acs.chemrev.7b00653","article-title":"Divergent Strategy in Natural Product Total Synthesis","volume":"118","author":"Li","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib95","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib96","series-title":"Ref. Module Neurosci. Biobehav. Psychol., Elsevier","article-title":"Neurotensin and Its Receptors\u2606, in","author":"Sarret","year":"2017"},{"key":"10.1016\/j.phrs.2024.107408_bib97","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-6147(99)01357-7","article-title":"Neurotensin and neurotensin receptors","volume":"20","author":"Vincent","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib98","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0163-7258(98)00009-6","article-title":"Mechanisms of Regulation of Neurotensin Receptors","volume":"79","author":"Hermans","year":"1998","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib99","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.peptides.2006.04.025","article-title":"Neurotensin and pain modulation","volume":"27","author":"Dobner","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2024.107408_bib100","doi-asserted-by":"crossref","first-page":"840","DOI":"10.2174\/1381612820666141027124915","article-title":"The roles of neurotensin and its analogues in pain","volume":"21","author":"Feng","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2024.107408_bib101","first-page":"645","article-title":"Neurotensin-induced antinociception in mice: antagonism by thyrotropin-releasing hormone","volume":"217","author":"Osbahr","year":"1981","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib102","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0006-8993(84)90619-X","article-title":"A mechanism for the analgesic effect of neurotensin as revealed by behavioral and electrophysiological techniques","volume":"324","author":"Behbehani","year":"1984","journal-title":"Brain Res"},{"key":"10.1016\/j.phrs.2024.107408_bib103","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bbr.2006.09.016","article-title":"Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice","volume":"175","author":"Bredeloux","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2024.107408_bib104","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1021\/acs.jmedchem.0c01726","article-title":"Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic","volume":"64","author":"Chartier","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib105","article-title":"Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog, Biomed. Pharmacother","volume":"141","author":"Chartier","year":"2021","journal-title":"Biomedecine Pharm."},{"key":"10.1016\/j.phrs.2024.107408_bib106","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0014-2999(77)90236-9","article-title":"Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli","volume":"46","author":"Clineschmidt","year":"1977","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib107","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0014-2999(79)90415-1","article-title":"Neurotensin: antinocisponsive action in rodents","volume":"54","author":"Clineschmidt","year":"1979","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib108","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0197-0186(88)90175-1","article-title":"Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin n","volume":"12","author":"Coquerel","year":"1988","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.phrs.2024.107408_bib109","first-page":"3741","article-title":"Spinal NTS2 receptor activation reverses signs of neuropathic pain","volume":"27","author":"T\u00e9treault","year":"2013","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.phrs.2024.107408_bib110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s42399-018-0009-4","article-title":"Are Opioids Effective in Relieving Neuropathic Pain?","volume":"1","author":"Schembri","year":"2019","journal-title":"SN Compr. Clin. Med."},{"key":"10.1016\/j.phrs.2024.107408_bib111","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ejpain.2011.07.008","article-title":"Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain","volume":"16","author":"Guillemette","year":"2012","journal-title":"Eur. J. Pain. Lond. Engl."},{"key":"10.1016\/j.phrs.2024.107408_bib112","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1021\/jm00136a004","article-title":"Synthesis of peptides by the solid-phase method. 6. Neurotensin, fragments, and analogues","volume":"24","author":"St-Pierre","year":"1981","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib113","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/open.201402031","article-title":"Structure-based evolution of subtype-selective neurotensin receptor ligands","volume":"3","author":"Schaab","year":"2014","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.phrs.2024.107408_bib114","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature11558","article-title":"Structure of the agonist-bound neurotensin receptor","volume":"490","author":"White","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107408_bib115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1432-1033.1982.tb05913.x","article-title":"Synthesis and characterization of neurotensin analogues for structure\/activity relationship studies. Acetyl-neurotensin-(8--13) is the shortest analogue with full binding and pharmacological activities","volume":"124","author":"Granier","year":"1982","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.phrs.2024.107408_bib116","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0014-2999(92)90314-T","article-title":"JMV 449: a pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse","volume":"219","author":"Dubuc","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib117","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-8993(91)90139-M","article-title":"Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem","volume":"557","author":"al-Rodhan","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.phrs.2024.107408_bib118","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1744-8069-6-86","article-title":"PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects","volume":"6","author":"Kleczkowska","year":"2010","journal-title":"Mol. Pain."},{"key":"10.1016\/j.phrs.2024.107408_bib119","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1016\/j.bmc.2010.06.073","article-title":"Role of 2\u2019,6\u2019-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds","volume":"18","author":"Balboni","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib120","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1734-1140(13)71064-8","article-title":"Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20","volume":"65","author":"Kleczkowska","year":"2013","journal-title":"Pharmacol. Rep. PR"},{"key":"10.1016\/j.phrs.2024.107408_bib121","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.3390\/ijms20235935","article-title":"Endomorphin-2- and Neurotensin- Based Chimeric Peptide Attenuates Airway Inflammation in Mouse Model of Nonallergic Asthma","volume":"20","author":"Russjan","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib122","first-page":"84","article-title":"Neurotensin-based hybrid peptide\u2019s anti-inflammatory activity in murine model of a contact sensitivity response","volume":"93","author":"Kaczy\u0144ska","year":"2016","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib123","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.brainres.2016.07.039","article-title":"Antinociceptive effect induced by a combination of opioid and neurotensin moieties vs. their hybrid peptide [Ile9]PK20 in an acute pain treatment in rodents","volume":"1648","author":"Kleczkowska","year":"2016","journal-title":"Brain Res"},{"key":"10.1016\/j.phrs.2024.107408_bib124","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejps.2014.06.018","article-title":"Role of neurotensin and opioid receptors in the cardiorespiratory effects of [Ile9]PK20, a novel antinociceptive chimeric peptide","volume":"63","author":"Kaczy\u0144ska","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib125","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.apsb.2020.04.014","article-title":"Novel opioid-neurotensin-based hybrid peptide with spinal long-lasting antinociceptive activity and a propensity to delay tolerance development","volume":"10","author":"Fr\u0105czek","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2024.107408_bib126","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2017.01.010","article-title":"Cardiovascular and respiratory activity of PK20, opioid and neurotensin hybrid peptide in anesthetized and awake rats","volume":"797","author":"Kaczy\u0144ska","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib127","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fendo.2013.00036","article-title":"Diverse Roles of Neurotensin Agonists in the Central Nervous System","volume":"4","author":"Boules","year":"2013","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.phrs.2024.107408_bib128","doi-asserted-by":"crossref","first-page":"12929","DOI":"10.1021\/acs.jmedchem.0c01376","article-title":"Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure\u2013Activity Relationship Studies","volume":"63","author":"Gonzalez","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib129","doi-asserted-by":"crossref","DOI":"10.1021\/acsptsci.4c00236","article-title":"Design, Synthesis, and In Vitro Characterization of Proteolytically-Stable Opioid-Neurotensin Hybrid Peptidomimetics","author":"De Neve","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib130","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bjp.0706929","article-title":"The MC4 receptor and control of appetite","volume":"149","author":"Adan","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib131","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1734-1140(09)70171-9","article-title":"Peripheral antinociceptive effects of MC4 receptor antagonists in a rat model of neuropathic pain \u2013 a biochemical and behavioral study","volume":"61","author":"Starowicz","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.phrs.2024.107408_bib132","doi-asserted-by":"crossref","DOI":"10.1111\/eos.12786","article-title":"Effects of melanocortin-4 receptor (MC4R) antagonist on neuropathic pain hypersensitivity in rats - A systematic review and meta-analysis","volume":"129","author":"Korczeniewska","year":"2021","journal-title":"Eur. J. Oral. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib133","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.pain.2005.07.003","article-title":"Inhibition of morphine tolerance by spinal melanocortin receptor blockade","volume":"117","author":"Starowicz","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.phrs.2024.107408_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108232","article-title":"Novel hybrid compounds, opioid agonist+melanocortin 4 receptor antagonist, as efficient analgesics in mouse chronic constriction injury model of neuropathic pain","volume":"178","author":"Starnowska-Sok\u00f3\u0142","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2024.107408_bib135","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/j.pain.0000000000002045","article-title":"Novel bifunctional hybrid compounds designed to enhance the effects of opioids and antagonize the pronociceptive effects of nonopioid peptides as potent analgesics in a rat model of neuropathic pain","volume":"162","author":"Piotrowska","year":"2021","journal-title":"PAIN"},{"key":"10.1016\/j.phrs.2024.107408_bib136","series-title":"Pept. Youth","first-page":"195","article-title":"Novel Analogues of Bifunctional Ligands for Opioid and Melanocortin 4 Receptor","author":"Kulkarni","year":"2009"},{"key":"10.1016\/j.phrs.2024.107408_bib137","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/ijms23020674","article-title":"Bifunctional Opioid\/Melanocortin Peptidomimetics for Use in Neuropathic Pain: Variation in the Type and Length of the Linker Connecting the Two Pharmacophores","volume":"23","author":"Witkowska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib138","first-page":"G628","article-title":"Cholecystokinin receptors","volume":"269","author":"Wank","year":"1995","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2024.107408_bib139","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1523\/JNEUROSCI.07-09-02967.1987","article-title":"Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists","volume":"7","author":"Hill","year":"1987","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.phrs.2024.107408_bib140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.physbeh.2012.03.004","article-title":"Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y","volume":"107","author":"Bowers","year":"2012","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.phrs.2024.107408_bib141","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1523\/JNEUROSCI.0743-05.2005","article-title":"Involvement of cholecystokininergic systems in anxiety-induced hyperalgesia in male rats: behavioral and biochemical studies","volume":"25","author":"Andre","year":"2005","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.phrs.2024.107408_bib142","article-title":"CCK2 receptors in chronic pain","volume":"11","author":"LaVigne","year":"2022","journal-title":"Neurobiol. Pain. Camb. Mass"},{"key":"10.1016\/j.phrs.2024.107408_bib143","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0304-3959(00)00290-6","article-title":"Supraspinal cholecystokinin may drive tonic descending facilitation mechanisms to maintain neuropathic pain in the rat","volume":"87","author":"Kovelowski","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.phrs.2024.107408_bib144","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41421-022-00420-3","article-title":"Structural insights into human brain-gut peptide cholecystokinin receptors","volume":"8","author":"Ding","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.phrs.2024.107408_bib145","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0024-3205(03)00390-4","article-title":"Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain","volume":"73","author":"Hruby","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib146","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1021\/jm050851n","article-title":"Design and synthesis of novel hydrazide-linked bifunctional peptides as delta\/mu opioid receptor agonists and CCK-1\/CCK-2 receptor antagonists","volume":"49","author":"Lee","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib147","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.peptides.2008.03.022","article-title":"Structure\u2013activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors","volume":"29","author":"Agnes","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2024.107408_bib148","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/jm061268p","article-title":"Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors","volume":"50","author":"Lee","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib149","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1021\/jm960078j","volume":"39","author":"Boteju","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib150","first-page":"750","article-title":"SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors","volume":"269","author":"Williams","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2011.04.024","article-title":"Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain","volume":"1395","author":"Hanlon","year":"2011","journal-title":"Brain Res"},{"key":"10.1016\/j.phrs.2024.107408_bib152","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1021\/jm050921q","article-title":"Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors","volume":"49","author":"Agnes","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib153","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0014-2999(91)90688-M","article-title":"Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide","volume":"200","author":"Slaninova","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib154","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1073\/pnas.82.22.7757","article-title":"Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine","volume":"82","author":"Yang","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2024.107408_bib155","first-page":"804","article-title":"Gene for pain modulatory neuropeptide NPFF: induction in spinal cord by noxious stimuli","volume":"55","author":"Vilim","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib156","doi-asserted-by":"crossref","first-page":"25965","DOI":"10.1074\/jbc.M004515200","article-title":"Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor","volume":"275","author":"Elshourbagy","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib157","doi-asserted-by":"crossref","first-page":"39324","DOI":"10.1074\/jbc.M004385200","article-title":"Identification and characterization of two G protein-coupled receptors for neuropeptide FF","volume":"275","author":"Bonini","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib158","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1073\/pnas.0502090103","article-title":"RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia","volume":"103","author":"Simonin","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2024.107408_bib159","first-page":"129","article-title":"A review of the role of anti-opioid peptides in morphine tolerance and dependence","volume":"12","author":"Rothman","year":"1992","journal-title":"Synap. N. Y. N."},{"key":"10.1016\/j.phrs.2024.107408_bib160","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/0024-3205(86)90391-7","article-title":"Existence of antiopiate systems as illustrated by MIF-1\/Tyr-MIF-1","volume":"39","author":"Galina","year":"1986","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib161","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0014-2999(93)90095-Y","article-title":"Antinociceptive effects of intrathecally administered F8Famide and FMRFamide in the rat","volume":"237","author":"Gouard\u00e8res","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib162","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/jpet.109.164384","article-title":"Neuropeptide FF receptors have opposing modulatory effects on nociception","volume":"334","author":"Lameh","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib163","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0196-9781(99)00028-5","article-title":"Chimeric peptide of Met-enkephalin and FMRFa induces antinociception and attenuates development of tolerance to morphine antinociception","volume":"20","author":"Gupta","year":"1999","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2024.107408_bib164","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1021\/jm00047a005","article-title":"Structure-activity study of neuropeptide FF: contribution of N-terminal regions to affinity and activity","volume":"37","author":"Gicquel","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib165","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/cbdd.12721","article-title":"NPYFa, A Chimeric Peptide of Met-Enkephalin, and NPFF Induces Tolerance-Free Analgesia","volume":"87","author":"Mudgal","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.phrs.2024.107408_bib166","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.regpep.2012.08.008","article-title":"Analgesic properties of chimeric peptide based on morphiceptin and PFRTic-amide","volume":"179","author":"Li","year":"2012","journal-title":"Regul. Pept."},{"key":"10.1016\/j.phrs.2024.107408_bib167","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/science.6259732","article-title":"Morphiceptin (NH4-tyr-pro-phe-pro-COHN2): a potent and specific agonist for morphine (mu) receptors","volume":"212","author":"Chang","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.phrs.2024.107408_bib168","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.peptides.2003.10.009","article-title":"Functional properties of Pfr(Tic)amide and BIBP3226 at human neuropeptide FF2 receptors","volume":"24","author":"Engstr\u00f6m","year":"2003","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2024.107408_bib169","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/bph.13489","article-title":"BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice","volume":"173","author":"Li","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib170","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/0024-3205(87)90065-8","article-title":"Bivalent opioid peptide analogues with reduced distances between pharmacophores","volume":"40","author":"Lipkowski","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173169","article-title":"Spinal administration of the multi-functional opioid\/neuropeptide FF agonist BN-9 produced potent antinociception without development of tolerance and opioid-induced hyperalgesia","volume":"880","author":"Zhang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib172","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.1021\/acs.jmedchem.6b01181","article-title":"Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib173","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0196-9781(01)00468-5","article-title":"Structure-activity relationships of neuropeptide FF: role of C-terminal regions","volume":"22","author":"Mazarguil","year":"2001","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2024.107408_bib174","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/med.2610090306","article-title":"Recent developments in the design of receptor specific opioid peptides","volume":"9","author":"Hruby","year":"1989","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib175","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/0024-3205(81)90226-5","article-title":"The preference of putative pro-enkephalins for different types of opiate receptors","volume":"29","author":"W\u00fcster","year":"1981","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib176","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0014-2999(81)90364-2","article-title":"Analogues of \u03b2-LPH61\u201364 posessing selective agonist activity at \u03bc-opiate receptors","volume":"70","author":"Handa","year":"1981","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib177","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.peptides.2018.10.010","article-title":"Analgesic activities of the mixed opioid and NPFF receptors agonist DN-9 in a mouse model of formalin-induced orofacial inflammatory pain","volume":"110","author":"Zhang","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2024.107408_bib178","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2016.03.017","article-title":"Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance","volume":"108","author":"Wang","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2024.107408_bib179","article-title":"Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice","volume":"9","author":"Wang","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2024.107408_bib180","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/0196-9781(93)90108-S","article-title":"Effects of F8Famide analogs on intestinal transit in mice","volume":"14","author":"Gicquel","year":"1993","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2024.107408_bib181","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/cphc.201900345","article-title":"Solvent-Enhanced Conformational Flexibility of Cyclic Tetrapeptides","volume":"20","author":"Berger","year":"2019","journal-title":"Chemphyschem Eur. J. Chem. Phys. Phys. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib182","doi-asserted-by":"crossref","first-page":"15709","DOI":"10.1021\/acs.jmedchem.0c01367","article-title":"Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid\/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib183","doi-asserted-by":"crossref","first-page":"13394","DOI":"10.1021\/acs.jmedchem.1c00694","article-title":"Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid\/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib184","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1021\/acschemneuro.2c00442","article-title":"OFP011 Cyclic Peptide as a Multifunctional Agonist for Opioid\/Neuropeptide FF Receptors with Improved Blood-Brain Barrier Penetration","volume":"13","author":"Zhang","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2024.107408_bib185","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1097\/j.pain.0000000000001262","article-title":"A bifunctional-biased mu-opioid agonist-neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects","volume":"159","author":"Drieu la Rochelle","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.phrs.2024.107408_bib186","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking beta-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.phrs.2024.107408_bib187","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.coph.2016.11.007","article-title":"Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics","volume":"32","author":"Siuda","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib188","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-pharmtox-052120-091058","article-title":"Biased Agonism: Lessons from Studies of Opioid Receptor Agonists","volume":"63","author":"Kelly","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.phrs.2024.107408_bib189","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.phrs.2024.107408_bib190","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.tips.2020.09.009","article-title":"Critical Assessment of G Protein-Biased Agonism at the \u03bc-Opioid Receptor","volume":"41","author":"Gillis","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib191","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased \u03bc-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"10","author":"Kliewer","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2024.107408_bib192","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/bph.15004","article-title":"Morphine-induced respiratory depression is independent of \u03b2-arrestin2 signalling","volume":"177","author":"Kliewer","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib193","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.bmc.2019.01.003","article-title":"Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation","volume":"27","author":"Zhang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib194","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.1021\/acs.jmedchem.4c00442","article-title":"Multitarget \u03bc-Opioid Receptor Agonists\u2500Neuropeptide FF Receptor Antagonists Induce Potent Antinociception with Reduced Adverse Side Effects","volume":"67","author":"De Neve","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib195","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2147\/DDDT.S372612","article-title":"Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review","volume":"17","author":"Daksla","year":"2023","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib196","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2013","article-title":"Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease","volume":"94","author":"Steinhoff","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib197","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/495704","article-title":"Biological and Pharmacological Aspects of the NK1-Receptor","volume":"2015","author":"Garcia-Recio","year":"2015","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.phrs.2024.107408_bib198","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/262784a0","article-title":"Substance P and analgesia","volume":"262","author":"Stewart","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2024.107408_bib199","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0006-8993(88)90579-3","article-title":"Facilitation of the tail-flick reflex by noxious cutaneous stimulation in the rat: antagonism by a substance P analogue","volume":"462","author":"Cridland","year":"1988","journal-title":"Brain Res"},{"key":"10.1016\/j.phrs.2024.107408_bib200","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0024-3205(83)90464-2","article-title":"An approach to the self regulatory mechanism of substance P actions: II. Biological activity of new synthetic peptide analogs related both to enkephalin and substance P","volume":"33","author":"Lipkowski","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib201","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0014-2999(91)90038-R","article-title":"Opioid and neurokinin activities of substance P fragments and their analogs","volume":"193","author":"Lei","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib202","first-page":"1142","article-title":"Inhibition of morphine tolerance development by a substance P-opioid","volume":"295","author":"Foran","year":"2000","journal-title":"Pept. chimera, J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib203","doi-asserted-by":"crossref","first-page":"7621","DOI":"10.1073\/pnas.130181897","article-title":"A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic","volume":"97","author":"Foran","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib204","article-title":"Synthesis and pharmacological analysis of a morphine\/substance P chimeric molecule with full analgesic potency in morphine-tolerant rats","volume":"13","author":"Kream","year":"2007","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res"},{"key":"10.1016\/j.phrs.2024.107408_bib205","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1016\/j.bmc.2012.09.003","article-title":"Synthesis, biological activity and structure-activity relationship of endomorphin-1\/substance P derivatives","volume":"20","author":"Varamini","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib206","first-page":"1586","article-title":"Chapter 216 - Opioid-Substance P Chimeric Peptides, in: A.J. Kastin (Ed.)","author":"Lipkowski","year":"2013","journal-title":"Handb. Biol. Act. Pept. Second Ed., Acad. Press, Boston"},{"key":"10.1016\/j.phrs.2024.107408_bib207","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejps.2016.07.009","article-title":"Biological evaluation and molecular docking studies of AA3052, a compound containing a \u03bc-selective opioid peptide agonist DALDA and d-Phe-Phe-d-Phe-Leu-Leu-NH2, a substance P analogue","volume":"93","author":"Kowalczyk","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib208","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1021\/jm00123a035","article-title":"Dermorphin analogues carrying an increased positive net charge in their \u201cmessage\u201d domain display extremely high mu opioid receptor selectivity","volume":"32","author":"Schiller","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib209","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.3390\/molecules24244460","article-title":"Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors","volume":"24","author":"Wtorek","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2024.107408_bib210","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1046\/j.1460-9568.2003.02887.x","article-title":"Inhibition of neurokinin-1\u2013substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons","volume":"18","author":"Powell","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.phrs.2024.107408_bib211","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejpain.2004.05.007","article-title":"Improving opioid effectiveness: from ideas to evidence","volume":"9","author":"Kalso","year":"2005","journal-title":"Eur. J. Pain."},{"key":"10.1016\/j.phrs.2024.107408_bib212","first-page":"25","article-title":"Bifunctional pharmacophores. Biological activities of the peptide analog containing both casomorphine-like and substance P antagonist-like active elements","volume":"44","author":"Lipkowski","year":"1992","journal-title":"Pol. J. Pharmacol. Pharm."},{"key":"10.1016\/j.phrs.2024.107408_bib213","first-page":"1373","article-title":"CHAPTER 191 - Opioid-Substance P Chimeric Peptides, in: A.J. Kastin (Ed.)","author":"Lipkowski","year":"2006","journal-title":"Handb. Biol. Act. Pept., Acad. Press, Burlingt."},{"key":"10.1016\/j.phrs.2024.107408_bib214","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejphar.2004.02.023","article-title":"Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid receptor agonist and tachykinin receptor antagonist moieties","volume":"488","author":"Bonney","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib215","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1021\/jm061369n","article-title":"Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta\/mu opioid receptor agonists and neurokinin-1 receptor antagonists","volume":"50","author":"Yamamoto","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib216","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1476-5381.2010.00824.x","article-title":"Spinal or systemic TY005, a peptidic opioid agonist\/neurokinin 1 antagonist, attenuates pain with reduced tolerance","volume":"161","author":"Largent-Milnes","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib217","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1021\/jm070332f","article-title":"A Structure\u2013Activity Relationship Study and Combinatorial Synthetic Approach of C-Terminal Modified Bifunctional Peptides That Are \u03b4\/\u03bc Opioid Receptor Agonists and Neurokinin 1 Receptor Antagonists","volume":"51","author":"Yamamoto","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib218","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.1021\/jm800389v","article-title":"The Importance of Micelle-Bound States for the Bioactivities of Bifunctional Peptide Derivatives for \u03b4\/\u03bc Opioid Receptor Agonists and Neurokinin 1 Receptor Antagonists","volume":"51","author":"Yamamoto","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib219","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/jpet.113.205245","article-title":"Building a Better Analgesic: Multifunctional Compounds that Address Injury-Induced Pathology to Enhance Analgesic Efficacy while Eliminating Unwanted Side Effects","volume":"347","author":"Largent-Milnes","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib220","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1021\/jm101023r","article-title":"Discovery of a Potent and Efficacious Peptide Derivative for \u03b4\/\u03bc Opioid Agonist\/Neurokinin 1 Antagonist Activity with a 2\u2032,6\u2032-Dimethyl-l-Tyrosine: In vitro, In vivo, and NMR-Based Structural Studies","volume":"54","author":"Yamamoto","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib221","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1016\/j.bmc.2009.08.035","article-title":"The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety","volume":"17","author":"Yamamoto","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib222","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1021\/jm100157m","article-title":"Biological and Conformational Evaluation of Bifunctional Compounds for Opioid Receptor Agonists and Neurokinin 1 Receptor Antagonists Possessing Two Penicillamines","volume":"53","author":"Yamamoto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib223","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1021\/jm900473p","article-title":"Improving Metabolic Stability by Glycosylation: Bifunctional Peptide Derivatives That Are Opioid Receptor Agonists and Neurokinin 1 Receptor Antagonists","volume":"52","author":"Yamamoto","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib224","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1016\/j.bmc.2011.08.027","article-title":"Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands","volume":"19","author":"Vardanyan","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib225","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.bmcl.2013.06.065","article-title":"Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities","volume":"23","author":"Nair","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107408_bib226","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1016\/j.bmcl.2015.06.030","article-title":"Discovery of tripeptide-derived multifunctional ligands possessing delta\/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities","volume":"25","author":"Nair","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107408_bib227","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1021\/acs.jmedchem.5b01170","article-title":"Discovery of Novel Multifunctional Ligands with \u03bc\/\u03b4 Opioid Agonist\/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain","volume":"58","author":"Giri","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib228","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/jm1016285","article-title":"Design of Novel Neurokinin 1 Receptor Antagonists Based on Conformationally Constrained Aromatic Amino Acids and Discovery of a Potent Chimeric Opioid Agonist-Neurokinin 1 Receptor Antagonist","volume":"54","author":"Ballet","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib229","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1756-6606-5-4","article-title":"In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera","volume":"5","author":"Guillemyn","year":"2012","journal-title":"Mol. Brain"},{"key":"10.1016\/j.phrs.2024.107408_bib230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejmech.2014.12.033","article-title":"Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist \u2013 Neurokinin-1 antagonist peptidomimetics","volume":"92","author":"Guillemyn","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib231","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1021\/acsmedchemlett.5b00359","article-title":"Dual Alleviation of Acute and Neuropathic Pain by Fused Opioid Agonist-Neurokinin 1 Antagonist Peptidomimetics","volume":"6","author":"Betti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107408_bib232","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1021\/acsmedchemlett.6b00381","article-title":"Hydrazone Linker as a Useful Tool for Preparing Chimeric Peptide\/Nonpeptide Bifunctional Compounds","volume":"8","author":"Dyniewicz","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107408_bib233","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1021\/acschemneuro.7b00226","article-title":"Analgesic Properties of Opioid\/NK1 Multitarget Ligands with Distinct in Vitro Profiles in Naive and Chronic Constriction Injury Mice","volume":"8","author":"Starnowska","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2024.107408_bib234","first-page":"3429","article-title":"Antinociceptive and Cytotoxic Activity of Opioid Peptides with Hydrazone and Hydrazide Moieties at the C-Terminus","volume":"25","author":"Dyniewicz","year":"2020","journal-title":"Mol. Basel Switz."},{"key":"10.1016\/j.phrs.2024.107408_bib235","doi-asserted-by":"crossref","first-page":"7738","DOI":"10.3390\/ijms21207738","article-title":"In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist\/NK1R Antagonist with Selective Cytotoxicity","volume":"21","author":"Matali\u0144ska","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib236","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s10989-020-10051-5","article-title":"Evaluation of Receptor Affinity, Analgesic Activity and Cytotoxicity of a Hybrid Peptide, AWL3020","volume":"26","author":"Matali\u0144ska","year":"2020","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib237","first-page":"5406","article-title":"Harnessing the Anti-Nociceptive Potential of NK2 and NK3 Ligands in the Design of New Multifunctional \u03bc\/\u03b4-Opioid Agonist-Neurokinin Antagonist Peptidomimetics","volume":"26","author":"Gadais","year":"2021","journal-title":"Mol. Basel Switz."},{"key":"10.1016\/j.phrs.2024.107408_bib238","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/j.jpainsymman.2022.06.002","article-title":"Cannabis in Palliative Care: A Systematic Review of Current Evidence","volume":"64","author":"Doppen","year":"2022","journal-title":"J. Pain. Symptom Manag."},{"key":"10.1016\/j.phrs.2024.107408_bib239","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.bjp.0706045","article-title":"Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice","volume":"144","author":"Tham","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-2999(96)00752-2","article-title":"Potentiation of \u03949-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of \u03bc- and \u03ba-opioid receptors","volume":"318","author":"Reche","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib241","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/jm4005219","article-title":"Bivalent ligands that target \u03bc opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance","volume":"56","author":"Le Naour","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib242","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","article-title":"SR141716A, a potent and selective antagonist of the brain cannabinoid receptor","volume":"350","author":"Rinaldi-Carmona","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2024.107408_bib243","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ejmech.2019.05.037","article-title":"Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors","volume":"178","author":"Dvor\u00e1csk\u00f3","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib244","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/14756366.2016.1260565","article-title":"Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors","volume":"32","author":"Mollica","year":"2017","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2011.02.038","article-title":"Imidazoline I2 receptors: Target for new analgesics?","volume":"658","author":"Li","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib246","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/pr.118.016311","article-title":"Imidazoline Receptor System: The Past, the Present, and the Future","volume":"72","author":"Bousquet","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib247","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bjp.0702031","article-title":"Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands","volume":"125","author":"Boronat","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib248","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2011.07.041","article-title":"Morphine-induced antinociception in the rat: Supra-additive interactions with imidazoline I2 receptor ligands","volume":"669","author":"Li","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib249","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0968-0896(01)00356-X","article-title":"Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for \u03bc opioid and I2-imidazoline receptors: synthesis and pharmacological screening","volume":"10","author":"Montero","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib250","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/S0968-0896(98)80005-9","article-title":"Ligand binding to I2 imidazoline receptor: The role of lipophilicity in quantitative structure\u2014activity relationship models","volume":"6","author":"Pigini","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib251","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1016\/j.bmc.2006.06.007","article-title":"Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the \u03bc-opioid receptor and I2\u2013imidazoline binding sites","volume":"14","author":"Dardonville","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib252","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bmcl.2003.10.048","article-title":"Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for \u03bc-opioid receptors and I2-imidazoline binding sites","volume":"14","author":"Dardonville","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107408_bib253","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3727\/096368915X687778","article-title":"Roles of kinins in the nervous system","volume":"24","author":"Negraes","year":"2015","journal-title":"Cell Transpl."},{"key":"10.1016\/j.phrs.2024.107408_bib254","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/pr.57.1.2","article-title":"International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences","volume":"57","author":"Leeb-Lundberg","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.phrs.2024.107408_bib255","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.pain.2013.01.003","article-title":"Characterisation and mechanisms of bradykinin-evoked pain in man using iontophoresis","volume":"154","author":"Paterson","year":"2013","journal-title":"PAIN"},{"key":"10.1016\/j.phrs.2024.107408_bib256","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1016\/j.bmcl.2015.08.014","article-title":"Design, Synthesis and Biological evaluation of Multifunctional Ligands Targeting Opioid and Bradykinin 2 Receptors","volume":"25","author":"Deekonda","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107408_bib257","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.phrs.2024.107408_bib258","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1460-9568.2004.03609.x","article-title":"Metabotropic glutamate receptor 5 localized in the limbic forebrain is critical for the development of morphine-induced rewarding effect in mice","volume":"20","author":"Aoki","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.phrs.2024.107408_bib259","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.brainres.2007.10.007","article-title":"mGluR5 antagonists that block calcium mobilization in vitro also reverse (S)-3,5-DHPG-induced hyperalgesia and morphine antinociceptive tolerance in vivo","volume":"1187","author":"Gabra","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/j.phrs.2024.107408_bib260","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/FBP.0b013e32834d13a2","article-title":"Metabotropic glutamate antagonists alone and in combination with morphine: comparison across two models of acute pain and a model of persistent, inflammatory pain","volume":"22","author":"Picker","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib261","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1097\/j.pain.0000000000001050","article-title":"Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice","volume":"158","author":"Peterson","year":"2017","journal-title":"PAIN"},{"key":"10.1016\/j.phrs.2024.107408_bib262","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2014.09.008","article-title":"Targeting putative mu opioid\/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model","volume":"743","author":"Smeester","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib263","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1097\/j.pain.0000000000001902","article-title":"The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioids","volume":"161","author":"Speltz","year":"2020","journal-title":"PAIN"},{"key":"10.1016\/j.phrs.2024.107408_bib264","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neuroscience.2023.02.006","article-title":"MMG22 Potently Blocks Hyperalgesia in Cisplatin-treated Mice","volume":"516","author":"Cataldo","year":"2023","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2024.107408_bib265","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(10)60354-6","article-title":"Ziconotide for treatment of severe chronic pain","volume":"375","author":"Schmidtko","year":"2010","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.phrs.2024.107408_bib266","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/nedt.2007.3.1.69","article-title":"Ziconotide: a review of its pharmacology and use in the treatment of pain","volume":"3","author":"McGivern","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.phrs.2024.107408_bib267","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.2174\/0929867043363884","article-title":"Ziconotide: neuronal calcium channel blocker for treating severe chronic pain","volume":"11","author":"Miljanich","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib268","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.neuron.2017.10.028","article-title":"CaV2.2 Gates Calcium-Independent but Voltage-Dependent Secretion in Mammalian Sensory Neurons","volume":"96","author":"Chai","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2024.107408_bib269","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40120-015-0035-z","article-title":"Intrathecal Ziconotide and Morphine for Pain Relief: A Case Series of Eight Patients with Refractory Cancer Pain, Including Five Cases of Neuropathic Pain","volume":"4","author":"de la Calle Gil","year":"2015","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib270","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/cbdd.12479","article-title":"Design, Synthesis and Biological Evaluation of Two Opioid Agonist and Cav 2.2 Blocker Multitarget Ligands","volume":"86","author":"Mollica","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.phrs.2024.107408_bib271","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.neuropharm.2013.03.002","article-title":"Potentiation of morphine-induced mechanical antinociception by \u03c3\u2081 receptor inhibition: role of peripheral \u03c3\u2081 receptors","volume":"70","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2024.107408_bib272","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/jpet.300.3.1070","article-title":"Sigma1 receptor modulation of opioid analgesia in the mouse","volume":"300","author":"Mei","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib273","first-page":"1583","article-title":"Selective antagonism of opioid analgesia by a sigma system","volume":"271","author":"Chien","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib274","first-page":"178","article-title":"Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial","volume":"15","author":"Bruna","year":"2018","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"10.1016\/j.phrs.2024.107408_bib275","doi-asserted-by":"crossref","first-page":"8211","DOI":"10.1021\/jm3007323","article-title":"Synthesis and biological evaluation of the 1-arylpyrazole class of \u03c3(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)","volume":"55","author":"D\u00edaz","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib276","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2013.04.018","article-title":"Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effects","volume":"711","author":"Vidal-Torres","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib277","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ejmech.2016.09.077","article-title":")-and (-)-Phenazocine enantiomers: Evaluation of their dual opioid agonist\/\u03c31 antagonist properties and antinociceptive effects","volume":"125","author":"Prezzavento","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib278","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1021\/jo01092a012","article-title":"Structures Related to Morphine. XII.1 (\u00b1)-2\u2019-Hydroxy-5,9-dimethyl-2-phenethyl-6,7-benzomorphan (NIH 7519) and Its Optical Forms","volume":"24","author":"MAY","year":"1959","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib279","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1021\/acs.jmedchem.9b01256","article-title":"4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual \u03bc-Opioid Receptor Agonists and \u03c31 Receptor Antagonists for the Treatment of Pain","volume":"63","author":"Garc\u00eda","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib280","doi-asserted-by":"crossref","first-page":"15508","DOI":"10.1021\/acs.jmedchem.0c01127","article-title":"Discovery of EST73502, a Dual \u03bc-Opioid Receptor Agonist and \u03c31 Receptor Antagonist Clinical Candidate for the Treatment of Pain","volume":"63","author":"Garc\u00eda","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib281","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106966","article-title":"IUPHAR Review - Bivalent and bifunctional opioid receptor ligands as novel analgesics","volume":"197","author":"Rehrauer","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107408_bib282","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bmcl.2008.10.134","article-title":"Syntheses and opioid receptor binding properties of carboxamido-substituted opioids","volume":"19","author":"Wentland","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107408_bib283","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1021\/jm800913d","volume":"51","author":"Kurimura","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib284","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.lfs.2009.02.025","article-title":"Bi- or multifunctional opioid peptide drugs","volume":"86","author":"Schiller","year":"2010","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib285","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/SPC.0000000000000129","article-title":"Simultaneous targeting of multiple opioid receptor types","volume":"9","author":"Bird","year":"2015","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.phrs.2024.107408_bib286","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cmdc.201500041","article-title":"New Approaches in the Design and Development of Cannabinoid Receptor Ligands: Multifunctional and Bivalent Compounds","volume":"10","author":"Nimczick","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2024.107408_bib287","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/bph.13809","article-title":"Targeting multiple opioid receptors \u2013 improved analgesics with reduced side effects?","volume":"175","author":"G\u00fcnther","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107408_bib288","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2018.11.007","article-title":"Neurokinin-1 receptor-based bivalent drugs in pain management: The journey to nowhere?","volume":"196","author":"Kleczkowska","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2024.107408_bib289","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1039\/D1MD00041A","article-title":"Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors","volume":"12","author":"De Neve","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113658","article-title":"Bifunctional \u03bc opioid and \u03c31 receptor ligands as novel analgesics with reduced side effects","volume":"223","author":"Zhuang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107408_bib291","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40263-022-00924-2","article-title":"Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation","volume":"36","author":"Coluzzi","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2024.107408_bib292","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jnr.24624","article-title":"Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse","volume":"100","author":"Kiguchi","year":"2022","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.phrs.2024.107408_bib293","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.3390\/ijms23052766","article-title":"Fentanyl Structure as a Scaffold for Opioid\/Non-Opioid Multitarget Analgesics","volume":"23","author":"Lipi\u0144ski","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2024.107408_bib294","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1021\/acs.jmedchem.2c01695","article-title":"Multitargeted Opioid Ligand Discovery as a Strategy to Retain Analgesia and Reduce Opioid-Related Adverse Effects","volume":"66","author":"Smith","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824003530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824003530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T19:55:37Z","timestamp":1731009337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824003530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":294,"alternative-id":["S1043661824003530"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107408","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multitarget ligands that comprise opioid\/nonopioid pharmacophores for pain management: Current state of the science","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107408"}}